Dr. James Liu is a neurosurgeon who specializes in the surgical and radiosurgical treatment of brain and spine tumors. Currently, he is an Assistant Member in the Department of Neuro-Oncology at Moffitt Cancer Center and an Assistant Professor of Oncologic Sciences at the University of South Florida. He received his undergraduate education from the University of Michigan. He received a medical degree from Case Western Reserve University School of Medicine. He obtained his residency training in neurosurgery at the Cleveland Clinic. He also completed a post-doctoral fellowship in Cancer Stem Cell Biology at the Cleveland Clinic, during which he was awarded the Congress of Neurological Surgeons Tumor Fellowship. He then completed a fellowship in neurosurgical oncology at Memorial Sloan Kettering Cancer Center.
Dr. Liu also leads a laboratory research effort focused on understanding the molecular mechanisms that drive the formation of brain tumors. In particular, the Liu Laboratory focuses on how a subset of the tumor population with tumor-initiating, or stem-like properties, contributes to the proliferation of brain tumors and their resistance to medical therapies. The Laboratory uses peptide screening technology against patient derived brain tumor cells to isolate novel receptors and targets that can be used to further characterize the mechanisms that drive these cells, for the development of future therapeutic strategies. The Laboratory also utilizes peptide screening technology to develop targeting agents that allow tumor detection at a cellular level, for improved visualization as well as earlier diagnosis of primary and metastatic brain tumors.
Education & Training
Memorial Sloan Kettering Cancer Center - Neurosurgical Oncology
Cleveland Clinic - Neurosurgery
Case Western Reserve University School of Medicine - MD
Vogelbaum MA, Kroll D, Etame A, Tran N, Liu J, Ford A, Sparr E, Kim Y, Forsyth P, Sahebjam S, Mokhtari S, Peguero E, Macaulay R. A Prospective Validation Study of the First 3D Digital Exoscope for Visualization of 5-ALA-Induced Fluorescence in High-Grade Gliomas. World Neurosurg. 2021 May.149:e498-e503. Pubmedid: 33561551.
Mills MN, Thawani C, Figura NB, Oliver DE, Soyano AE, Etame A, Robinson TJ, Liu JK, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Yu HM, Ahmed KA. Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases. J Neurooncol. 2021 May.152(3):591-601. Pubmedid: 33742358.
Mills MN, Naz A, Thawani C, Walker C, Figura NB, Kushchayev S, Oliver DE, Etame AB, Yu HM, Robinson TJ, Liu JKC, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Capecitabine and stereotactic radiation in the management of breast cancer brain metastases. BMC Cancer. 2021 May.21(1):552. Pubmedid: 33992087. Pmcid: PMC8126143.
Mills MN, Walker C, Thawani C, Naz A, Figura NB, Kushchayev S, Etame A, Yu HM, Robinson TJ, Liu J, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. BMC Cancer. 2021 Mar.21(1):223. Pubmedid: 33663447. Pmcid: PMC7934378.
Kim J, She C, Potez M, Huang P, Wu Q, Prager BC, Qiu Z, Bao S, Rich JN, Liu JKC. Phage display targeting identifies EYA1 as a regulator of glioblastoma stem cell maintenance and proliferation. Stem Cells. 2021 Jul.39(7):853-865. Pubmedid: 33594762.
Hsieh JK, Colby S, Nichols D, Kondylis E, Liu JKC. Delayed Development of Spinal Subdural Hematoma Following Cranial Trauma: A Case Report and Review of the Literature. World Neurosurg. 2020 Sep.141:44-51. Pubmedid: 32450315.
Liu JKC. Initial Approach to Patients with a Newly Diagnosed Solitary Brain Metastasis. Neurosurg Clin N Am. 2020 Oct.31(4):489-503. Pubmedid: 32921346.
Ward B, Wang C, Macaulay RJB, Liu JKC. Adult Intracranial Myxoid Mesenchymal Tumor with EWSR1-ATF1 Gene Fusion. World Neurosurg. 2020 Nov.143:91-96. Pubmedid: 32683005.
Glitza IC, Smalley KSM, Brastianos PK, Davies MA, McCutcheon I, Liu JKC, Ahmed KA, Arrington JA, Evernden BR, Smalley I, Eroglu Z, Khushalani N, Margolin K, Kluger H, Atkins MB, Tawbi H, Boire A, Forsyth P. Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell Melanoma Res. 2020 Jul.33(4):527-541. Pubmedid: 31916400.
Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Ann Chen Y, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2019 May.32(3):458-469. Pubmedid: 30712316. Pmcid: PMC7771318.
Figura NB, Rizk VT, Mohammadi H, Evernden B, Mokhtari S, Yu HM, Robinson TJ, Etame AB, Tran ND, Liu J, Washington I, Diaz R, Czerniecki BJ, Soliman H, Han HS, Sahebjam S, Forsyth PA, Ahmed KA. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy. Breast Cancer Res Treat. 2019 Jun.175(3):781-788. Pubmedid: 30859348.
Figura NB, Potluri TK, Mohammadi H, Oliver DE, Arrington JA, Robinson TJ, Etame AB, Tran ND, Liu JK, Soliman H, Forsyth PA, Sahebjam S, Yu HM, Han HS, Ahmed KA. CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases. J Neurooncol. 2019 Aug.144(3):583-589. Pubmedid: 31399935.
Liu JKC. Neurologic Deterioration Due to Brain Sag After Bilateral Craniotomy for Subdural Hematoma Evacuation. World Neurosurg. 2018 Jun.114:90-93. Pubmedid: 29524703.
Liu JK, Kshettry VR, Recinos PF, Kamian K, Schlenk RP, Benzel EC. Establishing a surgical skills laboratory and dissection curriculum for neurosurgical residency training. J Neurosurg. 2015 Nov.123(5):1331-1338. Pubmedid: 26052729.
Liu JK, Laufer I, Bilsky MH. Update on management of vertebral column tumors. CNS Oncol. 2014 Mar.3(2):137-147. Pubmedid: 25055019. Pmcid: PMC6128188.
Liu JK, Lubelski D, Schonberg DL, Wu Q, Hale JS, Flavahan WA, Mulkearns-Hubert EE, Man J, Hjelmeland AB, Yu J, Lathia JD, Rich JN. Phage display discovery of novel molecular targets in glioblastoma-initiating cells. Cell Death Differ. 2014 Aug.21(8):1325-1339. Pubmedid: 24832468. Pmcid: PMC4085538.
Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, Fang X, Sloan AE, Mao Y, Lathia JD, Min W, McLendon RE, Rich JN, Bao S. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell. 2013 Mar.153(1):139-152. Pubmedid: 23540695. Pmcid: PMC3638263.
Liu JK, Soliman H, Machado A, Deogaonkar M, Rezai AR. Intracranial hemorrhage after removal of deep brain stimulation electrodes. J Neurosurg. 2012 Mar.116(3):525-528. Pubmedid: 22136644.
Bidros DS, Liu JK, Vogelbaum MA. Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol. 2010 Jan.6(1):117-125. Pubmedid: 20021213.
Moskowitz SI, Liu J, Krishnaney AA. Postoperative complications associated with dural substitutes in suboccipital craniotomies. Neurosurgery. 2009 Mar.64(3 Suppl):ons28-ons33. Pubmedid: 19240570.
Federici T, Liu JK, Teng Q, Yang J, Boulis NM. A means for targeting therapeutics to peripheral nervous system neurons with axonal damage. Neurosurgery. 2007 May.60(5):911-918. Pubmedid: 17460527.
Federici T, Liu JK, Teng Q, Garrity-Moses M, Yang J, Boulis NM. Neuronal affinity of a C7C loop peptide identified through phage display. J Drug Target. 2006 Jun.14(5):263-271. Pubmedid: 16882546.
Zhao Z, Krishnaney A, Teng Q, Yang J, Garrity-Moses M, Liu JK, Venkiteswaran K, Subramanian T, Davis M, Boulis NM. Anatomically discrete functional effects of adenoviral clostridial light chain gene-based synaptic inhibition in the midbrain. Gene Ther. 2006 Jun.13(12):942-952. Pubmedid: 16511525.
Teng Q, Tanase D, Tanase DK, Liu JK, Garrity-Moses ME, Baker KB, Boulis NM. Adenoviral clostridial light chain gene-based synaptic inhibition through neuronal synaptobrevin elimination. Gene Ther. 2005 Jan.12(2):108-119. Pubmedid: 15496959.
Garrity-Moses ME, Teng Q, Liu J, Tanase D, Boulis NM. Neuroprotective adeno-associated virus Bcl-xL gene transfer in models of motor neuron disease. Muscle Nerve. 2005 Dec.32(6):734-744. Pubmedid: 16116646.
Teng Q, Garrity-Moses M, Federici T, Tanase D, Liu JK, Mazarakis ND, Azzouz M, Walmsley LE, Carlton E, Boulis NM. Trophic activity of Rabies G protein-pseudotyped equine infectious anemia viral vector mediated IGF-I motor neuron gene transfer in vitro. Neurobiol Dis. 2005 Dec.20(3):694-700. Pubmedid: 16005636.
Liu JK, Teng Q, Garrity-Moses M, Federici T, Tanase D, Imperiale MJ, Boulis NM. A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting. Neurobiol Dis. 2005 Aug.19(3):407-418. Pubmedid: 16023583.
Leung C, Lingbeek M, Shakhova O, Liu J, Tanger E, Saremaslani P, Van Lohuizen M, Marino S. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature. 2004 Mar.428(6980):337-341. Pubmedid: 15029199.
Tanase K, Teng Q, Krishnaney AA, Liu JK, Garrity-Moses ME, Boulis NM. Cervical spinal cord delivery of a rabies G protein pseudotyped lentiviral vector in the SOD-1 transgenic mouse. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. J Neurosurg Spine. 2004 Jul.1(1):128-136. Pubmedid: 15291033.
Garrity-Moses ME, Liu JK, Boulis NM. Molecular biology and gene therapy in the treatment of chronic pain. Neurosurg Clin N Am. 2003 Jul.14(3):419-435. Pubmedid: 14567143.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub